Venatorx Pharmaceuticals

Venatorx Pharmaceuticals Strikes Deal with Menarini Group for Global Rights to Cefepime-Taniborbactam

MALVERN, PA — Venatorx Pharmaceuticals recently granted exclusive commercial rights to Italy’s Menarini Group for its novel antibiotic, cefepime-taniborbactam. The agreement extends to 96 countries in Europe, Latin America, Middle …

Venatorx Pharmaceuticals Strikes Deal with Menarini Group for Global Rights to Cefepime-Taniborbactam Read More


Venatorx Pharmaceuticals

FDA Accepts Venatorx Pharmaceuticals’ New Drug Application for Cefepime-Taniborbactam

MALVERN, PA — Venatorx Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) recenlty accepted the company’s New Drug Application (NDA) for cefepime-taniborbactam, an investigational beta-lactam/beta-lactamase inhibitor (BL/BLI) antibiotic …

FDA Accepts Venatorx Pharmaceuticals’ New Drug Application for Cefepime-Taniborbactam Read More
medical news

The Rise of Metallo-Beta-Lactamases: Venatorx Pharmaceuticals Sheds Light on Carbapenem-Resistant Enterobacterales in the US

MALVERN, PA — Venatorx Pharmaceuticals recently highlighted two recent publications that provide important updates on the changing epidemiology of carbapenem-resistant Enterobacterales (CRE) globally and in the United States (US). According …

The Rise of Metallo-Beta-Lactamases: Venatorx Pharmaceuticals Sheds Light on Carbapenem-Resistant Enterobacterales in the US Read More